✦ LIBER ✦

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

✍ Scribed by Robert P Giugliano; Nihar R Desai; Payal Kohli; William J Rogers; Ransi Somaratne; Fannie Huang; Thomas Liu; Satishkumar Mohanavelu; Elaine B Hoffman; Shannon T McDonald; Timothy E Abrahamsen; Scott M Wasserman; Robert Scott; Marc S Sabatine

Book ID: 118553735
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 353 KB
Volume: 380
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)61770-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and tolerability of a

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

✍ Michael J Koren; Rob Scott; Jae B Kim; Beat Knusel; Thomas Liu; Lei Lei; Michael 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 384 KB

Safety and Efficacy of a Monoclonal Anti

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

✍ James M. McKenney; Michael J. Koren; Dean J. Kereiakes; Corinne Hanotin; Anne-Ca 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 732 KB

Design and Rationale of the LAPLACE-TIMI

Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

✍ Payal Kohli; Nihar R. Desai; Robert P. Giugliano; Jae B. Kim; Ransi Somaratne; F 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB